Home    About Us    Medic-All    Bio B2B    Hot Topic     Expo     Login | Join Now          
Bio B2BOrient Pharma Co., Ltd. 〉New combination for treating Sialorrhea

New combination for treating Sialorrhea

New combination for treating Sialorrhea

Orient Pharma's phase IIa study is completed to show effective reduction in excessive saliva secretion in patients with Parkinson's Disease.

Request for Collaboration
Overview
• Combination of two compounds with different Mechnism of Action to reduce the secreting of saliva.
• First oral treatment for sialorrhoea of Parkinson's Disease.
• Results of Phase IIa study, published in the 17th International Congress of Parkinson's Disease and Movement Disorders, shows efficacy and safety.
Application
Sialorrhea (excessive saliva secretion) in patients with neural disorders, e.g. Parkinson's Disease, Stroke, Amyotrophic Lateral Ssclerosis (ALS), Cerebral Palsy.
Patent Portfolio
Patents granted in US, EU, Japan, Australia, Taiwan, etc.
Collaboration Options
Open for global collaboration
People who like this also like
  • PipelinePipeline
  • AmCAD UOAmCAD UO
  • Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)Broad-spectrum therapeutic antibody against novel carbohydrate antigen (CHO-A04)
  • TRIA11TRIA11
  • TLC590TLC590
  • Platform_NanoX™Platform_NanoX™
  • FB317FB317
  • Complete and Comprehensive Design/Production CapabilitiesComplete and Comprehensive Design/Production Capabilities
  • R&D ManagementR&D Management
  • FLISA (IgE/IgG test)FLISA (IgE/IgG test)